Management of Thrombosis Associated with Covishield

Mashiullah Khan, Neeku Singh, Akshay Sharma, Ashok Kumar
Haridwar University

Abstract: Covishield, the Indian variant of the Oxford-AstraZeneca COVID-19 vaccine, has been pivotal in the global vaccination campaign. However, concerns regarding thrombotic events, particularly Thrombosis with Thrombocytopenia Syndrome (TTS), have emerged. This review discusses the incidence, clinical management, and recommendations for thrombosis associated with Covishield.

Keywords: Covishield, thrombosis, Thrombosis with Thrombocytopenia Syndrome, vaccine safety, anticoagulation management.

INTRODUCTION

Thrombosis related to Covishield, although rare, has raised significant concern among healthcare providers and the public. Understanding the mechanisms, clinical presentation, and management of TTS is critical for ensuring patient safety and maintaining confidence in vaccination efforts.

Incidence and Mechanism

TTS following Covishield vaccination is characterized by thrombosis accompanied by low platelet counts. The incidence of TTS is estimated to be around 1 in 100,000 doses, primarily affecting younger populations. The exact mechanism is still under investigation, but it is thought to involve an immune-mediated response leading to platelet activation.

Clinical Presentation

Patients with TTS may present with symptoms such as:

- Severe headache: Often persistent and unlike typical post-vaccination headaches.
- Visual disturbances: Indicating potential cerebral venous sinus thrombosis.
- Abdominal pain: Suggestive of splanchnic vein thrombosis.
- Leg swelling or pain: Indicative of deep vein thrombosis.
- Skin manifestations: Such as petechiae or ecchymosis.

Diagnosis

Diagnosis of TTS should be considered in patients presenting with symptoms within 4 to 28 days post-vaccination. Essential diagnostic steps include:

- Complete Blood Count (CBC): To check platelet levels.
- Imaging Studies: CT or MRI for suspected cerebral thrombosis; ultrasound for suspected DVT.
- D-dimer Levels: Elevated levels may suggest thrombosis.

Management Strategies

1. Immediate Assessment:
   - Prompt clinical evaluation is essential for timely intervention.
   - Consultation with a hematologist may be warranted.
2. Treatment Protocols:
   - Anticoagulation: Standard anticoagulants like unfractionated heparin are typically recommended. However, clinicians should avoid platelet-inhibiting agents such as aspirin in the acute phase due to the risk of further bleeding.
   - Monitoring Platelet Counts: Continuous monitoring is vital to assess the efficacy of treatment and detect any further drop in platelet levels.
3. Corticosteroids:
   - In cases where there is significant thrombocytopenia or severe symptoms, corticosteroids may be administered to dampen the immune response.
4. Supportive Care:
   - Patients should be closely monitored for signs of complications such as hemorrhage or organ dysfunction.
5. Patient Education:

- Informing patients about symptoms of TTS is crucial. Early recognition can significantly improve outcomes.

Risk Assessment and Prevention

While the overall risk of TTS is low, specific populations (e.g., younger women) may be at higher risk. Vaccination protocols may include:

- Informed Consent: Providing detailed information regarding potential risks associated with vaccination.
- Risk Stratification: Evaluating patient history and comorbidities before administration.

CONCLUSION

Thrombosis associated with Covishield is a rare but serious adverse effect requiring prompt recognition and management. Continued monitoring and research are essential to refine treatment protocols and improve patient outcomes. Vaccination remains a critical public health tool, and understanding the risks helps ensure safe practices.

REFERENCES

[1] WHO. (2021). Safety considerations for COVID-19 vaccines.
[2] European Medicines Agency (EMA). (2021). COVID-19 Vaccine AstraZeneca: Assessment report.